Dare Competitors

Stocks . USA . 
Stock . Dare Bioscience
DARE Stock  USD 2.11  0.02  0.96%   
Dare Bioscience competes with Adlai Nortye, Ainos, FibroBiologics, Common, NextCure, and Lexaria Bioscience; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Dare Bioscience competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Dare Bioscience to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Dare Bioscience Correlation with its peers.
For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Dare Bioscience competition on your existing holdings.
  
Build AI portfolio with Dare Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.112.104.97
Details
Intrinsic
Valuation
LowRealHigh
1.414.287.15
Details
Naive
Forecast
LowNextHigh
0.042.014.88
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.982.112.25
Details

Dare Bioscience Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dare Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Dare and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dare Bioscience does not affect the price movement of the other competitor.

High positive correlations

PTHS
+ 0.68
LEXX
AIMD
+ 0.61
ANL
PTHS
+ 0.58
EDSA
PTHS
+ 0.56
ANL
ASBP
+ 0.56
FBLG
CRIS
+ 0.55
FBLG
  

High negative correlations

NXTC
- 0.81
FBLG
PULM
- 0.63
ANL
PULM
- 0.57
AIMD
EDSA
- 0.54
FBLG
FBLG
- 0.52
AIMD
CRIS
- 0.48
NXTC

Risk-Adjusted Indicators

There is a big difference between Dare Stock performing well and Dare Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dare Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ANL  2.11  0.23  0.06  0.58  2.49 
(2.56)
 5.33 
(4.52)
 15.01 
AIMD  4.19  0.67  0.13  5.72  4.05 
(5.36)
 7.87 
(7.61)
 49.34 
FBLG  3.81 (0.53) 0.00 (2.05) 0.00 
 0.00 
 7.32 
(8.89)
 24.12 
NXTC  3.80  1.02  0.18 (13.68) 4.49 
(4.81)
 8.96 
(4.67)
 60.54 
LEXX  4.82  0.15  0.03  0.13  7.01 
(5.95)
 11.22 
(9.18)
 64.28 
PULM  2.54 (0.27) 0.00 (0.14) 0.00 
 0.00 
 6.02 
(6.41)
 17.50 
CRIS  2.63 (0.19) 0.00 (0.22) 0.00 
 0.00 
 6.21 
(5.46)
 16.44 
EDSA  2.56  0.25  0.07  0.46  2.87 
(2.99)
 7.00 
(4.60)
 17.10 
ASBP  7.66  0.36  0.04  0.34  8.05 
(12.92)
 10.64 
(13.89)
 109.52 
PTHS  4.12  0.75  0.13 (1.49) 4.28 
(5.00)
 13.96 
(7.88)
 36.92 
All Fundamental Data

Dare Bioscience Competitive Analysis

The better you understand Dare Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dare Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dare Bioscience's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DARE ANL AIMD FBLG NXTC LEXX PULM CRIS EDSA ASBP
 0.96 
 2.11 
Dare
 0.60 
 1.65 
Adlai
 1.93 
 3.69 
Ainos
 7.32 
 0.44 
FibroBiologics,
 3.49 
 9.20 
NextCure
 2.20 
 0.93 
Lexaria
 0.21 
 4.84 
Pulmatrix
 1.23 
 1.61 
Curis
 1.86 
 2.74 
Edesa
 2.86 
 0.34 
Aspire
Market Volatility
(90 Days Market Risk)
Moderately volatile
Relatively risky
Very risky
Very risky
Slightly risky
Dangerous
Slightly risky
Slightly risky
Moderately volatile
Out of control
Market Performance
(90 Days Performance)
Weakest
Fair
Fair
Weakest
Good
Soft
Weakest
Weakest
Mild
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Strong
Strong
Risky
High
Low
Risky
Risky
Small
High
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Current Ratio
2.17
N/A
0.53
N/A
33.87
40.09
8.19
7.69
2.68
N/A
Net Asset
22.1 M
71.27 M
28.82 M
16.45 M
80.86 M
8.87 M
9.94 M
41.27 M
3.81 M
147.99 K
EBITDA
(23.41 M)
(48.08 M)
(9.44 M)
(13.74 M)
(54.34 M)
(5.68 M)
(7.04 M)
(42.57 M)
(5.98 M)
(11.65 M)
Operating Margin
180.8
-12.21
-803.28
N/A
N/A
-21.55
N/A
-3.0
N/A
N/A
Current Valuation
26.98 M
31.81 M
26.91 M
24.55 M
(15.25 M)
15.26 M
8.27 M
12.29 M
19.17 M
23.15 M
Price To Book
10.75
2.57
1.49
26.3
0.49
3.56
3.17
4.32
4.11
N/A
Retained Earnings
(175.29 M)
(429.32 M)
(52.75 M)
(35.52 M)
(380.14 M)
(51.56 M)
(297.16 M)
(1.24 B)
(58.59 M)
(2.78 M)
Current Asset
7.58 M
N/A
N/A
N/A
46.99 M
N/A
8.34 M
85.5 M
6.92 M
N/A
Beta
1.14
-0.88
2.27
N/A
1.34
0.8
1.64
3.86
0.075
0.91
Number Of Employees
21
123
44
13
43
7
2
34
16
4
Shares Outstanding
13.48 M
31.24 M
4.77 M
41.89 M
2.68 M
22.23 M
3.65 M
12.5 M
7.34 M
49.53 M
Cash Flow From Operations
5.39 M
(51.82 M)
(5.81 M)
(11.9 M)
(40.8 M)
(4.96 M)
(10.72 M)
(39.56 M)
(4.89 M)
(265.19 K)
Total Debt
1.3 M
27.23 M
12 M
10.55 M
5.95 M
137.37 K
996 K
2.95 M
19.87 K
1.27 M
Return On Equity
-9.95
-1.03
-0.98
-5.6
-1.06
-1.53
-0.79
-29.51
-0.7
N/A
Return On Asset
-0.63
-0.33
-0.31
-0.88
-0.53
-0.85
-0.47
-0.6
-0.4
N/A
Number Of Shares Shorted
185.02 K
2.04 K
12.37 K
2.03 M
10.91 K
1 M
5.92 K
197.84 K
9.33 K
1.8 M
Book Value Per Share
-1.41
0.69
2.68
0.021
12.68
0.28
1.3
-1.31
0.7
-0.14
Current Liabilities
17.82 M
N/A
N/A
N/A
5.53 M
N/A
4.11 M
10.76 M
581.49 K
N/A
Total Asset
22.1 M
71.27 M
28.82 M
16.45 M
80.86 M
8.87 M
9.94 M
41.27 M
3.81 M
147.99 K
Debt To Equity
0.022
2.44
5.3
N/A
0.01
0.007
0.044
0.075
0.003
N/A
Short Ratio
1.37
0.21
0.16
1.95
1.43
0.82
0.33
2.72
0.08
0.02
Target Price
10.75
9.0
N/A
10.25
17.5
5.33
10.0
16.33
10.33
N/A
Shares Owned By Institutions
6.59
0.19
0.12
12.28
32.57
10.32
9.33
34.47
29.99
2.9
Market Capitalization
28.44 M
60.96 M
17.61 M
18.28 M
24.62 M
20.64 M
17.68 M
20.12 M
20.12 M
20.24 M
Price To Earning
-43.44
12.24
N/A
N/A
-25.44
N/A
-1.3
-3.21
-3.96
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
0.03
N/A
N/A
N/A
N/A
N/A
Price To Sales
751.51
31.42
158.8
N/A
9.52
33.51
5892.35
1.76
120478.0
N/A
Net Income
(4.05 M)
(51.87 M)
(14.86 M)
(11.16 M)
(55.65 M)
(5.81 M)
(9.56 M)
(43.39 M)
(6.17 M)
(1.31 M)
Earnings Per Share
-2.16
-1.62
-4.52
-0.36
-25.97
-0.68
-1.71
-4.62
-1.26
-0.58
Shares Owned By Insiders
11.48
8.5
56.46
19.56
14.79
6.42
0.66
7.23
28.71
33.07
Revenue
9.78 K
N/A
20.73 K
N/A
N/A
464.28 K
7.81 M
10.91 M
N/A
N/A
Working Capital
(3.16 M)
18.7 M
382.86 K
1.5 M
62.23 M
6.8 M
8.99 M
7.36 M
(157.21 K)
(1.54 M)
Cash And Equivalents
40.39 M
541 K
1.75 M
N/A
185.49 M
7.34 M
42.91 M
98.69 M
12.81 M
N/A
Cash Per Share
0.48
-0.79
0.09
N/A
6.68
1.23
12.67
1.02
0.83
N/A
Gross Profit
(14.32 M)
1.94 M
91.23 K
N/A
(54.2 M)
613.2 K
(7.16 M)
(26.76 M)
311.2 K
N/A
Day Typical Price
2.1
1.64
3.68
0.43
9.27
0.93
4.84
1.62
2.76
0.33
Accumulation Distribution
0.0421
0.0359
0.0373
0.0889
0.11
0.0526
0.0265
0.0595
0.11
0.11
Market Facilitation Index
0.09
0.06
0.14
0.04
1.06
0.05
0.13
0.1
0.33
0.04
Daily Balance Of Power
0.2222
(0.17)
0.5
0.75
0.2925
0.4
(0.08)
(0.20)
0.1515
(0.25)
Period Momentum Indicator
0.02
(0.01)
0.07
0.03
0.31
0.02
(0.01)
(0.02)
0.05
(0.01)
Rate Of Daily Change
1.01
0.99
1.02
1.07
1.03
1.02
1.0
0.99
1.02
0.97
Day Median Price
2.09
1.64
3.68
0.43
9.31
0.93
4.85
1.63
2.78
0.33
Price Action Indicator
0.025
0.005
0.045
0.025
0.045
0.015
(0.01)
(0.03)
(0.01)
0.005
Relative Strength Index
46.22
39.78
60.46
34.71
61.8
43.99
51.46
31.71
51.04
42.53
Coefficient Of Variation
(1,148)
1056.58
972.92
(981.85)
709.96
2181.71
(2,108)
(2,638)
1158.9
3522.03
Mean Deviation
2.23
2.11
4.19
3.81
3.8
4.82
2.54
2.63
2.56
7.66
Jensen Alpha
(0.31)
0.2277
0.673
(0.53)
1.02
0.1508
(0.27)
(0.19)
0.2532
0.3599
Total Risk Alpha
(0.60)
(0.07)
(0.11)
(1.09)
0.1633
(0.57)
(0.58)
(0.54)
(0.12)
(1.48)
Sortino Ratio
N/A
0.063
0.1344
N/A
0.1783
0.0337
N/A
N/A
0.073
0.0388
Downside Variance
N/A
8.79
20.39
N/A
27.63
65.98
N/A
N/A
9.76
99.12
Standard Deviation
2.87
2.87
6.73
4.93
7.26
7.82
3.47
3.45
3.63
16.59
Kurtosis
0.8704
0.6452
17.38
0.1699
12.99
7.66
0.6132
0.6046
2.49
23.08
Potential Upside
3.88
5.33
7.87
7.32
8.96
11.22
6.02
6.21
7.0
10.64
Treynor Ratio
(0.42)
0.5774
5.72
(2.05)
(13.68)
0.1321
(0.14)
(0.22)
0.4559
0.3414
Maximum Drawdown
11.21
15.01
49.34
24.12
60.54
64.28
17.5
16.44
17.1
109.52
Variance
8.22
8.24
45.32
24.29
52.65
61.2
12.01
11.87
13.15
275.39
Market Risk Adjusted Performance
(0.41)
0.5874
5.73
(2.04)
(13.67)
0.1421
(0.13)
(0.21)
0.4659
0.3514
Risk Adjusted Performance
(0.05)
0.0684
0.0749
(0.06)
0.0994
0.0385
(0.02)
(0.02)
0.0635
0.0278
Skewness
(0.62)
0.0646
3.12
0.179
2.18
0.0722
0.2505
0.5782
0.9661
4.18
Semi Deviation
N/A
2.49
4.05
N/A
4.49
7.01
N/A
N/A
2.87
8.05
Information Ratio
(0.12)
0.0651
0.0902
(0.12)
0.1291
0.035
(0.07)
(0.06)
0.0629
0.0233
Value At Risk
(4.93)
(4.52)
(7.61)
(8.89)
(4.67)
(9.18)
(6.41)
(5.46)
(4.60)
(13.89)
Expected Short fall
N/A
(2.56)
(5.36)
N/A
(4.81)
(5.95)
N/A
N/A
(2.99)
(12.92)
Downside Deviation
N/A
2.97
4.52
N/A
5.26
8.12
N/A
N/A
3.12
9.96
Semi Variance
N/A
6.18
16.38
N/A
20.12
49.12
N/A
N/A
8.26
64.85

Dare Bioscience Competition Performance Charts

Five steps to successful analysis of Dare Bioscience Competition

Dare Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dare Bioscience in relation to its competition. Dare Bioscience's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Dare Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dare Bioscience's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dare Bioscience, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Dare Bioscience position

In addition to having Dare Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Toys Thematic Idea Now

Toys
Toys Theme
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Dare Bioscience is a strong investment it is important to analyze Dare Bioscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Dare Bioscience's future performance. For an informed investment choice regarding Dare Stock, refer to the following important reports:
How To Invest In Dare
Details
Is Dare Stock a good investment?
Details
What is Dare Bioscience's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out Dare Bioscience Correlation with its peers.
For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dare Bioscience. If investors know Dare will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dare Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dare Bioscience is measured differently than its book value, which is the value of Dare that is recorded on the company's balance sheet. Investors also form their own opinion of Dare Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Dare Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dare Bioscience's market value can be influenced by many factors that don't directly affect Dare Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Dare Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dare Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dare Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY